Skip to main content

What the FDA labels say about taking them together

Rifampin and vemurafenib

Vemurafenib's FDA label of August 28, 2026 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name vemurafenib. The vemurafenib label: “Strong CYP3A4 Inducers Coadministration of ZELBORAF with rifampin, a strong CYP3A4 inducer, decreased vemurafenib plasma concentrations and may result in decreased efficacy.”

Check it at the source: the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.); the vemurafenib FDA label on DailyMed (effective August 28, 2026, Genentech, Inc.).

What does the rifampin label say about vemurafenib?

Rifampin's label (effective February 11, 2026) does not name vemurafenib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed

What does the vemurafenib label say about rifampin?

Vemurafenib label, drug interactions

Strong CYP3A4 Inducers Coadministration of ZELBORAF with rifampin, a strong CYP3A4 inducer, decreased vemurafenib plasma concentrations and may result in decreased efficacy.

Source: FDA drug label (ZELBORAF), NDA202429 (Hoffmann La Roche), as published by Genentech, Inc., effective August 28, 2026 (SPL set 38eea320-7e0c-485a-bc30-98c3c45e2763), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

13Rifampin generic labelers
0Vemurafenib generic labelers
RifampinVemurafenib
Labeled forn/an/a
Boxed warningNoNo
Pharmacy cost (NADAC)$0.679 per capsule 300 mg capsulen/a
Shortage nowIn shortageNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?